Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACE-041 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ACE-041 | EXPERIMENTAL | Patients assigned to 1 of 9 possible dosing groups |
| Name | Type | Description |
|---|---|---|
| ACE-041 | BIOLOGICAL | Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered. |
Inclusion Criteria: * Diagnosis of metastatic or unresectable advanced solid tumors (solid tumors must be measurable) or relapsed/refractory multiple myeloma for which the disease has progressed despite available standard therapies or for which no standard therapy exists. * Life expectancy of at le...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ACE-041 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It was evaluated in a Phase 1 clinical trial that also included patients with relapsed or refractory multiple myeloma. The drug is not approved and remains in clinical development.
ACE-041 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company sponsored the Phase 1 clinical trial of this investigational monoclonal antibody for advanced solid tumors.
ACE-041 is in Phase 1 clinical development. A single Phase 1 trial has been completed, and there are no active trials currently listed. The drug is investigational and has not been approved by regulatory authorities for any use.
ACE-041 has been studied in one completed Phase 1 clinical trial, identified as NCT00996957. The trial enrolled 37 participants with advanced solid tumors or relapsed or refractory multiple myeloma and was conducted in the United States.
ACE-041 is the primary name used for this investigational monoclonal antibody in clinical development. No alternative names have been reported for this drug in the available clinical trial information.